Celgene
Signal active
Investment Firm
Overview
Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.
There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.
In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.
Highlights
Founded
1986
Industry
Biotechnology
Employees
10001+
Investment
65
Lead Investment
17
Exits
31
Stages
Early Stage Venture, Late Stage Venture, Private Equity
Investor Type
N/A
Location
United States, North America
Contact Information
Social
Profile Resume
Celgene, established in 1986 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Private Equity investments across Biotechnology, Health Care, Medical Device, Financial Services, Venture Capital, Finance, Pharmaceutical, FinTech, Life Science, Medical. The organization boasts a portfolio of 65 investments, with an average round size of $54.5M and 31 successful exits. Their recent investments include FerroKin Biosciences, Clarus Ventures, Burrill & Company, HealthCap, MP Healthcare Venture Management. The highest investment round they participated in was $302.6B. Among their most notable exits are FerroKin Biosciences and Clarus Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Employees
Investment portfolio
Celgene has made 65 investments. Their most recent investment was on Oct 15, 2019, when Cyteir Therapeutics raised $40.2M.
Celgene has made 16 diversity investments. Their most recent diversity investment was on Aug 06, 2019, when Cleave Therapeutics raised $12.0M.
investments
65
Diversity investments
16
Lead investments
17
Number of exits
31
Investments
65
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Aug 21, 2019 | Oncorus | Biotechnology | 79.5M |
| Sep 05, 2019 | immatics biotechnologies | Biotechnology | 75.0M |
| Sep 11, 2019 | Anokion | Biotechnology | 40.0M |
| Oct 15, 2019 | Cyteir Therapeutics | Biotechnology | 40.2M |
Oncorus
immatics biotechnologiesExits
31
Funding Timeline
Funding rounds
65
Investors
0
Funds
0
Funding Rounds
65
Celgene has raised 65 rounds. Their latest funding was raised on Oct 15, 2019 from a Series B - Cyteir Therapeutics round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Aug 21, 2019 | Series B - Oncorus | - | 79.5M | - |
| Sep 05, 2019 | Venture Round - immatics biotechnologies | - | 75.0M | - |
| Sep 11, 2019 | Series B - Anokion | - | 40.0M | - |
| Oct 15, 2019 | Series B - Cyteir Therapeutics | - | 40.2M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.